Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
Loading...
Citations
Altmetric:
Altmetric::
Download
Associated Records
Authors
File Licence
Editors
Date
2022-11-01
Source Title
Viruses
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Melbourne Authors
Affiliation
Minerva Elements
Document Type
Journal Article
Subject Code
Citation
McAuley, A. J., Jansen van Vuren, P., Mohammed, M. U. R., Faheem, , Goldie, S., Riddell, S., Gödde, N. J., Styles, I. K., Bruce, M. P., Chahal, S., Keating, S., Blasdell, K. R., Tachedjian, M., O’Brien, C. M., Singanallur, N. B., Viana, J. N., Vashi, A. V., Kirkpatrick, C. M., MacRaild, C. A. ,... Vasan, S. S. (2022). Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection. Viruses, 14 (11), https://doi.org/10.3390/v14112417.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways to develop new and alternative therapeutic options to manage the ongoing pandemic. Given circa 7817 licenced compounds available from Compounds Australia that can be screened, this paper demonstrates the utility of commercially available ex vivo/3D airway and alveolar tissue models. These models are a closer representation of in vivo studies than in vitro models, but retain the benefits of rapid in vitro screening for drug efficacy. We demonstrate that several existing drugs appear to show anti-SARS-CoV-2 activity against both SARS-CoV-2 Delta and Omicron Variants of Concern in the airway model. In particular, fluvoxamine, as well as aprepitant, everolimus, and sirolimus, has virus reduction efficacy comparable to the current standard of care (remdesivir, molnupiravir, nirmatrelvir). Whilst these results are encouraging, further testing and efficacy studies are required before clinical use can be considered.